24 Sep CAR T Therapy: What Recent Research Is Showing
CAR T therapy has been around for a while now, but the research has not slowed down. What started as a last-resort option for a narrow group of blood cancer patients has grown into something researchers are now testing in earlier treatment stages, in new cancer types, and in combination with other therapies. Here is a look at where things stand.
For years, CAR-T therapy was mostly reserved for patients who had already tried everything else and seen it fail. That is shifting. Recent phase 3 clinical trials — including ZUMA-7 and TRANSFORM — showed significant improvements in event-free survival when CAR T-cell therapy was used earlier as a second-line treatment rather than waiting until multiple prior therapies had failed. According to the NCI (National Cancer Institute), CAR T-cell therapies work by engineering a patient's own T-cells to recognize and attack cancer cells, and the FDA has now approved multiple CAR T products for several blood cancers — with clinical research continuing to expand both the indications and the timing of their use.
[caption id="attachment_76221" align="aligncenter" width="500"]
Pixabay[/caption]
Dr. Ben Jerry Gonzales[/caption]
Mr. Itay Shalom[/caption]
[caption id="attachment_76207" align="alignleft" width="113"]
Prof. Ami Citri.jpg[/caption]
Description: How to direct evolution in the lab: e. coli bacteria lacking their major attachment capabilities were incubated with human cells in a petri dish. After infection, the plate was washed repeatedly to remove the floating bacteria, and the few bacteria that were able to attach to the human cells remained in the plate. These few bacteria were collected and grown, then used for another cycle of infection. Four successive cycles of selection generated bacteria with highly efficient attachment ability. Credit: Noam Yedidi, Ilan Rosenshine's lab.[/caption]